Canton Strategic Holdings, Inc. (CNTN) Stock Analysis

Canton Strategic Holdings completed its transition from clinical-stage biotechnology to a pure-play digital-asset treasury and blockchain-infrastructure company after rebranding from Tharimmune on February 18, 2026 and divesting Gravitas Life Sciences on July 17. Its two revenue streams are locking-as-a-service and Canton Network validation. In Q2 2026, its first reporting period under the new model, revenue reached $1,495,859, including $1,304,633 from locking and $191,226 from validation. **The operating model is commercially nascent but tied to structural network requirements**, while the company’s 3,714,204,876 Canton Coins were valued at $523.35 million. The balance sheet held $37.24 million of cash, only $2.63 million of current liabilities, and zero debt. Despite this liquidity, GAAP losses were $19.25 million in Q2 and $66.60 million in the first half, largely because of unrealized token losses and stock compensation. At approximately $2.20, market capitalization was $175.30 million, or 0.36x-0.37x book value and 195.77x sales. Near-term catalysts are validator-weight expansion from 0.5 toward 15.0 by Q1 2028, potential execution of the $50 million buyback, and DTCC-related tokenization activity.